Human anti-Varicella zoster virus (VZV) gH IgM (clone M1416), Recombinant

Recombinant human anti-Varicella zoster virus VZV gH (clone M1416) IgM antibody, produced in HEK293 cells and purified by ion exchange chromatography and ammonium sulphate precipitation.

PRODUCT DETAILS – Human anti-Varicella zoster virus (VZV) gH IgM (clone M1416), Recombinant

• Isotype: human IgM
• Clone Number: M1416
• Presented as Liquid in 50mM HEPES, 150mM NaCl, pH8.0

BACKGROUND

Varicella zoster virus (VZV) is an exclusively human, neurotropic alphaherpesvirus that causes varicella (chickenpox) during primary infection and herpes zoster (shingles) when the virus reactivates from latency in sensory ganglia, with the greatest disease burden observed in older adults and people with impaired immunity. The viral envelope presents several key surface glycoproteins, notably glycoproteins E (gE), B (gB), and the gH/gL complex, which are dominant targets of the humoral immune response and are critical for virion membrane fusion, host cell entry, and direct cell to cell spread of infection (Sullivan et al., 2018). Functional studies using monoclonal antibodies have demonstrated that gH/gL together with gB constitute the minimal machinery required for VZV fusion, and that monoclonal antibodies directed against gH can strongly neutralize virus, block cell to cell transmission, and alter glycoprotein distribution in infected cells (Shiraki et al., 2011).

Recombinant VZV monoclonal antibodies offer a renewable and well characterized alternative to traditional hybridoma derived monoclonals for dissecting glycoprotein specific antibody responses (Birlea et al., 2013; Sullivan et al., 2018). Human recombinant monoclonal antibodies isolated after Zostavax vaccination have been shown to recognize conformational epitopes within the gH/gL complex and to effectively neutralize VZV infection in vitro, thereby enabling high resolution analyses of membrane fusion events and epitope specificity (Birlea et al., 2013). Alongside recombinant gE based assays, such as indirect ELISAs employing purified gE ectodomain to detect anti VZV antibodies in clinical samples (Niu et al., 2022), these recombinant reagents underpin contemporary VZV serology, vaccine immunogenicity assessment, and the rational engineering of antibodies with optimized specificity and effector functions for diagnostic and potential therapeutic applications (Sullivan et al., 2018).

REFERENCES

Birlea M et al. Human anti varicella zoster virus (VZV) recombinant monoclonal antibody produced after Zostavax immunization recognizes the gH/gL complex and neutralizes VZV infection. J Virol. 2013

Sullivan NL et al. Breadth and functionality of varicella zoster virus glycoprotein specific antibodies identified after Zostavax vaccination in humans. J Virol. 2018.

Shiraki K et al. Neutralizing anti gH antibody of varicella zoster virus modulates distribution of gH and induces gene regulation, mimicking latency. J Virol. 2011.

Niu Y et al. Development of an indirect ELISA kit for rapid detection of varicella zoster virus antibody by glycoprotein E. Front Microbiol. 2022.